Logo image of AKTX

AKARI THERAPEUTICS PLC-ADR (AKTX) Stock Price, Quote, News and Overview

NASDAQ:AKTX - Nasdaq - US00972G2075 - ADR - Currency: USD

1.17  +0.01 (+1.3%)

AKTX Quote, Performance and Key Statistics

AKARI THERAPEUTICS PLC-ADR

NASDAQ:AKTX (7/3/2025, 8:27:09 PM)

1.17

+0.01 (+1.3%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High4.4
52 Week Low0.85
Market Cap37.65M
Shares32.18M
Float211.10K
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-18 2025-08-18
IPO01-31 2014-01-31


AKTX short term performance overview.The bars show the price performance of AKTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -5 -10

AKTX long term performance overview.The bars show the price performance of AKTX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of AKTX is 1.17 USD. In the past month the price decreased by -13.33%. In the past year, price decreased by -59.23%.

AKARI THERAPEUTICS PLC-ADR / AKTX Daily stock chart

AKTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.43 334.34B
AMGN AMGEN INC 14.37 160.37B
GILD GILEAD SCIENCES INC 14.44 139.01B
VRTX VERTEX PHARMACEUTICALS INC N/A 118.03B
REGN REGENERON PHARMACEUTICALS 12.35 59.10B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 43.28B
ARGX ARGENX SE - ADR 94.52 33.18B
ONC BEONE MEDICINES LTD-ADR 6.26 26.56B
BNTX BIONTECH SE-ADR N/A 26.44B
NTRA NATERA INC N/A 22.09B
BIIB BIOGEN INC 8.4 19.47B
SMMT SUMMIT THERAPEUTICS INC N/A 18.23B

About AKTX

Company Profile

AKTX logo image Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company is headquartered in Boston, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2014-01-31. The firm is engaged in the development of antibody drug conjugates (ADCs) and advanced therapies for autoimmune and inflammatory diseases, including geographic atrophy (GA). Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. The firm is conducting pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). The company is conducting a phase III clinical trial in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The firm's pipeline also includes the PH-1 ADC Platform for oncology, PHP-303 program for genetic disease, liver disease and inflammation, specifically for Alpha-1 antitrypsin deficiency (AATD) and acute respiratory distress syndrome (ARDS), including COVID-19.

Company Info

AKARI THERAPEUTICS PLC-ADR

22 Boston Wharf Road, Fl 7

Boston MASSACHUSETTS W1G 9RT US

CEO: Clive Richardson

Employees: 9

AKTX Company Website

AKTX Investor Relations

Phone: 16463500702

AKARI THERAPEUTICS PLC-ADR / AKTX FAQ

What is the stock price of AKARI THERAPEUTICS PLC-ADR today?

The current stock price of AKTX is 1.17 USD. The price increased by 1.3% in the last trading session.


What is the ticker symbol for AKARI THERAPEUTICS PLC-ADR stock?

The exchange symbol of AKARI THERAPEUTICS PLC-ADR is AKTX and it is listed on the Nasdaq exchange.


On which exchange is AKTX stock listed?

AKTX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for AKARI THERAPEUTICS PLC-ADR stock?

7 analysts have analysed AKTX and the average price target is 7.14 USD. This implies a price increase of 510.26% is expected in the next year compared to the current price of 1.17. Check the AKARI THERAPEUTICS PLC-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is AKARI THERAPEUTICS PLC-ADR worth?

AKARI THERAPEUTICS PLC-ADR (AKTX) has a market capitalization of 37.65M USD. This makes AKTX a Nano Cap stock.


How many employees does AKARI THERAPEUTICS PLC-ADR have?

AKARI THERAPEUTICS PLC-ADR (AKTX) currently has 9 employees.


What are the support and resistance levels for AKARI THERAPEUTICS PLC-ADR (AKTX) stock?

AKARI THERAPEUTICS PLC-ADR (AKTX) has a support level at 1.12 and a resistance level at 1.17. Check the full technical report for a detailed analysis of AKTX support and resistance levels.


Should I buy AKARI THERAPEUTICS PLC-ADR (AKTX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does AKARI THERAPEUTICS PLC-ADR (AKTX) stock pay dividends?

AKTX does not pay a dividend.


When does AKARI THERAPEUTICS PLC-ADR (AKTX) report earnings?

AKARI THERAPEUTICS PLC-ADR (AKTX) will report earnings on 2025-08-18.


What is the Price/Earnings (PE) ratio of AKARI THERAPEUTICS PLC-ADR (AKTX)?

AKARI THERAPEUTICS PLC-ADR (AKTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.21).


What is the Short Interest ratio of AKARI THERAPEUTICS PLC-ADR (AKTX) stock?

The outstanding short interest for AKARI THERAPEUTICS PLC-ADR (AKTX) is 15.23% of its float. Check the ownership tab for more information on the AKTX short interest.


AKTX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

AKTX Financial Highlights

Over the last trailing twelve months AKTX reported a non-GAAP Earnings per Share(EPS) of -1.21. The EPS increased by 20% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -39.14%
ROE -89.03%
Debt/Equity 0.15
Chartmill High Growth Momentum
EPS Q2Q%90%
Sales Q2Q%N/A
EPS 1Y (TTM)20%
Revenue 1Y (TTM)N/A

AKTX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to AKTX. The Buy consensus is the average rating of analysts ratings from 7 analysts.


Ownership
Inst Owners0.98%
Ins Owners34.4%
Short Float %15.23%
Short Ratio1.23
Analysts
Analysts82.86
Price Target7.14 (510.26%)
EPS Next Y-5.88%
Revenue Next YearN/A